Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy
Authors
Keywords
-
Journal
Human Cell
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-27
DOI
10.1007/s13577-023-00990-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance
- (2022) Jie Lian et al. DIGESTIVE AND LIVER DISEASE
- WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers
- (2021) Mei-Hua Jin et al. Gastric Cancer
- Karyotype Aberrations in Action: The Evolution of Cancer Genomes and the Tumor Microenvironment
- (2021) Nicolaas C. Baudoin et al. Genes
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
- (2021) Joseph Chao et al. JAMA Oncology
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns
- (2021) Yannik Bollen et al. NATURE GENETICS
- Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD ‐1/ PD‐L1 Blockade Therapies
- (2021) Zhaoli Tan et al. ONCOLOGIST
- Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma
- (2021) Pei-Jhang Chiang et al. Biology-Basel
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
- (2021) Miao Huang et al. International Journal of General Medicine
- Tumor Endothelial Cell–Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway
- (2020) Kazuhiro Taguchi et al. MOLECULAR CANCER RESEARCH
- Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer
- (2019) Yasuhiro Koh et al. Clinical Lung Cancer
- Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer
- (2019) Yingjie Chen et al. BMC CANCER
- Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis
- (2019) Xiao Liu et al. Science Advances
- Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
- (2019) Melanie Janning et al. Cancers
- Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers
- (2019) Yue Zhao et al. SEMINARS IN CANCER BIOLOGY
- PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients
- (2019) Lina Zhang et al. CANCER LETTERS
- Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance
- (2018) Yilin Li et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status
- (2018) Lei Wang et al. Cancer Medicine
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
- (2016) Yilin Li et al. BRITISH JOURNAL OF CANCER
- Effects of aneuploidy on gene expression: implications for cancer
- (2015) Milena Dürrbaum et al. FEBS Journal
- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
- (2013) W. Q. Sheng et al. ANNALS OF ONCOLOGY
- Causes and consequences of aneuploidy in cancer
- (2012) David J. Gordon et al. NATURE REVIEWS GENETICS
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors
- (2009) Tomoshige Akino et al. AMERICAN JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started